Skip to main content
ESC Heart Failure logoLink to ESC Heart Failure
. 2022 Aug 17;9(5):3666. doi: 10.1002/ehf2.14108

Erratum

PMCID: PMC9715839  PMID: 35975636

In the paper by Oh et al., 1 the authors noticed an error in Table 2, entry for ‘EF change’ under column ‘Later use (n = 48)’. The correct data is 13.4 ± 12.5 instead of 413.4 ± 12.5.

The publisher apologizes for this error.

Reference

  • 1. Oh J‐H, Lee J‐M, Lee H‐J, Hwang J, Lee CH, Cho Y‐K, Park H‐S, Yoon H‐J, Chung J‐W, Kim H, Nam C‐W, Han S, Hur S‐H, Youn J‐C, Kim I‐C. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients. ESC Heart Fail. 2022; 9: 2435–2444. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from ESC Heart Failure are provided here courtesy of Wiley

RESOURCES